MA50038A - Anticorps anti-pd-l1 de et son utilisation - Google Patents

Anticorps anti-pd-l1 de et son utilisation

Info

Publication number
MA50038A
MA50038A MA050038A MA50038A MA50038A MA 50038 A MA50038 A MA 50038A MA 050038 A MA050038 A MA 050038A MA 50038 A MA50038 A MA 50038A MA 50038 A MA50038 A MA 50038A
Authority
MA
Morocco
Prior art keywords
antibodies
Prior art date
Application number
MA050038A
Other languages
English (en)
Inventor
Shorena Archuadze
Sergei Barbashov
Vasily Ignatiev
Yan Lavrovsky
Alexey Repik
Mikhail Samsonov
Ting Xu
Original Assignee
R Pharm Overseas Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by R Pharm Overseas Inc filed Critical R Pharm Overseas Inc
Publication of MA50038A publication Critical patent/MA50038A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
MA050038A 2017-04-18 2018-04-18 Anticorps anti-pd-l1 de et son utilisation MA50038A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2017028206 2017-04-18

Publications (1)

Publication Number Publication Date
MA50038A true MA50038A (fr) 2020-07-08

Family

ID=63856823

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050038A MA50038A (fr) 2017-04-18 2018-04-18 Anticorps anti-pd-l1 de et son utilisation

Country Status (16)

Country Link
US (1) US20210115143A1 (fr)
EP (1) EP3612565A4 (fr)
JP (2) JP2020517239A (fr)
KR (1) KR102323960B1 (fr)
CN (1) CN110856446A (fr)
AU (1) AU2018256392B2 (fr)
BR (1) BR112019021828B1 (fr)
CA (1) CA3059447A1 (fr)
CL (1) CL2019002953A1 (fr)
CO (1) CO2019012118A2 (fr)
EA (1) EA201900443A1 (fr)
MA (1) MA50038A (fr)
MX (1) MX2019012461A (fr)
PH (1) PH12019502302A1 (fr)
SG (1) SG11201909041SA (fr)
WO (1) WO2018195226A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
WO2018083248A1 (fr) 2016-11-03 2018-05-11 Kymab Limited Anticorps, combinaisons comprenant des anticorps, biomarqueurs, utilisations et procédés
JP2022513043A (ja) * 2018-11-14 2022-02-07 ルーブリック・セラピューティクス・インコーポレイテッド 操作されたｃｄ２５ポリペプチドおよびその使用
CN109929037B (zh) * 2019-04-01 2023-03-17 华博生物医药技术（上海）有限公司 针对程序性死亡配体的结合物及其应用
JP7302010B2 (ja) * 2019-04-11 2023-07-03 スクリップス コリア アンチボディ インスティチュート プログラム細胞死タンパク質リガンド－１（ｐｄ－ｌ１）に対する抗体及びその用途
CN112996815B (zh) * 2019-04-26 2024-02-20 天境生物科技(上海)有限公司 人pd-l1抗体
US20210403568A1 (en) * 2020-06-29 2021-12-30 Cai Gu Huang Biopharmaceutical formulation of anti-pd-1, anti-pd-l1, and anti-vegfr therapeutic monoclonal antibodies and method for treating nsclc by inhalation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2454587C (fr) * 2001-07-25 2012-11-13 Protein Design Labs, Inc. Formulation pharmaceutique lyophilisee stable d'anticorps igg
EP4169951A1 (fr) * 2008-12-09 2023-04-26 F. Hoffmann-La Roche AG Anticorps anti-pd-l1 et leur utilisation pour améliorer la fonction des lymphocytes t
WO2015061668A1 (fr) * 2013-10-25 2015-04-30 Dana-Farber Cancer Institute, Inc. Anticorps monoclonaux anti-pd-l1 et fragments de ceux-ci
CA2935375C (fr) * 2014-01-06 2023-08-08 The Trustees Of The University Of Pennsylvania Anticorps pd1 et pdl1 et combinaisons de vaccin et utilisation de celles-ci pour l'immunotherapie
US9688754B2 (en) * 2014-02-20 2017-06-27 Alder Biopharmaceuticals, Inc. Anti-ACTH antibodies and use thereof
CN105777906B (zh) * 2014-12-19 2019-04-23 苏州丁孚靶点生物技术有限公司 抗pd-l1全人抗体及其应用
CA2978942A1 (fr) * 2015-03-13 2016-09-22 Cytomx Therapeutics, Inc. Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procedes d'utilisation
KR102543323B1 (ko) * 2016-10-30 2023-06-14 상하이 헨리우스 바이오테크, 인크. 항-pd-l1 항체 및 변이체

Also Published As

Publication number Publication date
EP3612565A4 (fr) 2021-06-16
MX2019012461A (es) 2019-12-11
EA201900443A1 (ru) 2020-03-06
AU2018256392A1 (en) 2019-10-17
JP2023025003A (ja) 2023-02-21
KR102323960B1 (ko) 2021-11-10
US20210115143A1 (en) 2021-04-22
CO2019012118A2 (es) 2020-04-01
AU2018256392B2 (en) 2024-05-16
CA3059447A1 (fr) 2018-10-25
BR112019021828B1 (pt) 2022-09-20
CL2019002953A1 (es) 2020-01-10
JP2020517239A (ja) 2020-06-18
EP3612565A1 (fr) 2020-02-26
CN110856446A (zh) 2020-02-28
WO2018195226A1 (fr) 2018-10-25
BR112019021828A2 (pt) 2020-03-24
SG11201909041SA (en) 2019-11-28
PH12019502302A1 (en) 2020-09-21
KR20190141169A (ko) 2019-12-23

Similar Documents

Publication Publication Date Title
KR102162129B9 (ko) 항-갈렉틴-9 항체 및 이의 용도
MA44776A (fr) Anticorps anti-vista humain et leur utilisation
MA50038A (fr) Anticorps anti-pd-l1 de et son utilisation
MA46525A (fr) Anticorps anti-lag-3 et compositions
MA53434A (fr) Anticorps anti-tigit
IL273411A (en) Antibody against PD-L1 and its uses
MA47268A (fr) Anticorps anti-gpc3
MA44659A (fr) Anticorps anti-tim-3 et compositions
DK3383916T3 (da) Anti-CD73-antistoffer og anvendelser deraf
DK3625259T3 (da) Anti-sirpalpha-antistoffer
MA52884A (fr) Anticorps anti-il-11
MA52742A (fr) Anticorps bispécifiques dll3-cd3
MA42043A (fr) Anticorps anti-ox40 et procédés d'utilisation de ceux-ci
MA46057A (fr) Anticorps anti-ctla4
MA49687A (fr) Anticorps anti-ctla-4 et leurs utilisations
MA50948A (fr) Anticorps et procédés d'utilisation de ceux-ci
MA47311A (fr) Anticorps anti-tgf-bêta et leur utilisation
MA43018A (fr) Anticorps anti-pd1 et procédés d'utilisation
KR20180084817A (ko) 항-siglec-9 항체 및 이의 이용 방법
MA42243A (fr) Anticorps de facteur xi et méthodes d'utilisation
MA52284A (fr) Anticorps anti-hla-g et leur utilisation
MA51552A (fr) Anticorps anti-ox40 et procédés d'utilisation
MA52285A (fr) Anticorps multispécifiques et leur utilisation
MA45543A (fr) Anticorps anti-peptides n3pglu amyloïdes bêta et utilisations associées
MA49398A (fr) Anticorps monoclonaux anti-igf-1r et utilisations de ceux-ci